UBS initiates coverage on 6 pharma stocks. Sun Pharma, Cipla among top buys

September 28, 2024

Global brokerage firm UBS has initiated coverage on several pharma stocks, highlighting potential upsides and challenges within the sector. The report points to weakening trends in both India and the US, with underappreciated growth slowdowns in these markets. UBS has provided a mixed outlook, issuing both ‘Buy’ and ‘Sell’ ratings on a range of pharmaceutical stocks.Here is a list of 6 pharma stocks on which UBS initiated coverage:

More To Explore

Brent slides over 3%, hits lowest level since 2021

Oil prices plummeted to their lowest levels since 2021 due to new U.S. tariffs announced by President Trump and increased output by OPEC+. Brent and

April 4, 2025

Trump’s tariff hikes signal impoverishment day, not liberation day: Chris Wood of Jefferies

Jefferies’ Chris Wood criticizes Trump’s sweeping new tariffs, calling April 2 “an impoverishment day.” With steep levies on key Asian economies, analysts warn of global

April 4, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003